Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOTAL Trial of total neoadjuvant treatment with or without tislelizumab for locally advanced rectal cancer
2025-522120-28-00Phase 2Authorised
- Sponsor
- Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR, Rabin Medical Center
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of tislelizumab in rectal cancer (2 arms), sponsored by Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR, Rabin Medical Center. Primary endpoint: 3-year total mesorectal excision-free survival. Planned start Mar 2026; status: authorised.
02
Drugs
tislelizumab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on 2025-522120-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522120-28-00.